Business
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg(R) in acute Graft-versus Host Disease in Europe
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg(R) in acute Graft-versus Host Disease in
About this update from Maat Pharma
[{"type":"text","content":"LYON, France - Clinigen's hemato-oncology expertise and leading European position in hospital distribution and market access make this team the ideal fit to bring this therapy to patients.MaaT Pharma (EURONEXT: MAAT - the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announces the signature of a license and commercial agreement with Clinigen, a global specialty pharmaceutical services group and a leading European player in hospital distribution and market access, to streamline the pathway for ensuring access to this medicine across Europe 1. With this partnership, MaaT Pharma demonstrates its capability to supply products to pharmaceutical companies, including those specializing in rare diseases while ensuring scale-ups for commercial and extending its cash runway into January 2026.\nHerve Affagard, CEO and co-founder of MaaT Pharma says: 'This deal is a pivotal step in bridging MaaT Pharma's innovation with healthcare professionals who care for patients with aGvHD. Clinigen's hemato-oncology expertise and leading European position in hospital distribution and market access make this team the ideal fit to bring this therapy to patients and we're confident that this new relationship will maximize the full revenue generation potential of full revenue generation potential of Xervyteg (R) (MaaT013). I look forward to working closely with the Clinigen team as we prepare for a successful launch.'Jerome Charton, CEO of Clinigen, says: ' Following the EMA's acceptance of MaaT Pharma's submission of an application for assessment for MaaT013 in June, we are very excited about this new relationship. This collaboration brings a novel technology to the forefront of rare disease and oncology care. We're proud to play a leading role in ensuring access across Europe to this innovative therapy, and we look forward to working closely with MaaT Pharma as we prepare for potential launch.'\nTransaction Terms\nUnder the terms of the agreement, MaaT Pharma will grant Clinigen exclusive European rights to distribute this medicine for the treatment of patients with aGvHD, if approved by the EMA. MaaT Pharma will receive an upfront payment of EUR10.5 million and additional eligible payme...